The WHO has created a Cancer Pain Relief Programme and developed guide
lines for the treatment of cancer pain. Implementation of the analgesi
c guidelines, assurance of drug availability (specifically opioids), e
ducation of healthcare professionals, and designating cancer pain as a
priority for all national cancer control programmes are the major goa
ls. Recent studies of medical students, physicians, nurses and state m
edical boards demonstrate a significant lack of knowledge with regard
to the theoretical and practical understanding of the use of analgesic
drugs, particularly opioids, in the management of cancer pain. Commun
ication between physicians and patients about pain symptoms has also b
een shown to be problematic. Limited availability of opioids, their ex
cessive regulation, and the lack of use of alternatives to systemic an
algesics also prevent adequate management. Although analgesic drug the
rapy is the mainstay of treatment, opioid use remains a controversial
issue. Some of the controversies include their role in the management
of neuropathic pain, which has been suggested to be 'opioid-resistant'
, as well as the choice of opioid drug. A third controversy is the rou
te of administration. The impetus for the development of novel routes
has come from the goals of maximising analgesia, minimising side effec
ts, and providing convenient dosing schedules for patients who require
parenteral administration. Other important controversial issues are t
he development of tolerance and the relationship of pain management to
patient requests for physician-assisted suicide and euthanasia.